TABLE 3.
Genotypes and allelic distribution of VAMP2 26 bp Ins/Del polymorphism in AD, MD patients and CT subjects.
| VAMP2 26 bp Ins/Del (%) | Del/Del | Ins/Del | Ins/Ins | Del (Del/Del + Ins/Del) | Ins | Del |
| MD/MCI-MD2 (n = 152) |
4.6 | 23.0 | 72.4 | 27.6 | 83.9 | 16.13 |
| AD/MCI-AD (n = 196) | 1.0 | 26.5 | 72.5 | 27.5 | 85.7 | 14.3 |
| CT1 (n = 248) | 0.8 | 20.9 | 78.3 | 21.7 | 88.7 | 11.3 |
AD, Alzheimer’s disease; CT, subject without cognitive decline; MD, mixed dementia; MCI-AD, Mild Cognitive Impairment evolved to Alzheimer’s Disease; MCI-MD, Mild Cognitive Impairment evolved to Mixed Dementia.
1AD/MCI-AD vs. MD/MCI-MD vs. CT: p = 0.032; d.f.: 4; χ2 = 10.56; 2MD/MCI-MD vs. CT: p = 0.036; d.f.: 2; χ2 = 6.65; 3MD/MCI-MD vs. CT: p = 0.05; OR: 1.51; 95% CI: 0.99–2.28.